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Background: High EREG and AREG expression, and left-sided primary tumours are associated with superior efficacy of anti-
epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (CRC), but a unifying explanation of these
findings is lacking.
Methods: RNA-seq, gene expression arrays, and DNA methylation profiling were completed on 179 CRC tumours. Results were
validated using independent The Cancer Genome Atlas data sets. An independent cohort of 198 KRAS wild-type metastatic CRC
tumours was tested for CpG island methylator phenotype (CIMP) status, and progression-free survival (PFS) with the first anti-EGFR
regimen was retrospectively determined.
Results: EREG and AREG expression was highly inversely correlated with methylation and was inversely associated with right-
sided primary tumour, BRAF mutation, and CIMP-high status. Treatment of CRC cell lines with hypomethylating agents decreased
methylation and increased expression of EREG. Inferior PFS with anti-EGFR therapy was associated with CIMP-high status, BRAF
mutation, NRAS mutation, and right-sided primary tumour on univariate analysis. Among known BRAF/NRAS wild-type tumours,
inferior PFS remained associated with CIMP-high status (median PFS 5.6 vs 9.0 mo, P¼ 0.023).
Conclusions: EREG and AREG are strongly regulated by methylation, and their expression is associated with CIMP status and
primary tumour site, which may explain the association of primary tumour site and EREG/AREG expression with anti-EGFR therapy
efficacy.
With the development of therapies for metastatic colorectal cancer
(CRC) targeting the epidermal growth factor receptor (EGFR),
such as cetuximab and panitumumab, there has been significant
effort to identify rational biomarkers of resistance or susceptibility.
Initially, mutations in KRAS codons 12 and 13 were found to be
predictive biomarkers of lack of response to anti-EGFR therapies
(Amado et al, 2008; Karapetis et al, 2008; Van Cutsem et al, 2009;
Bokemeyer et al, 2011), and more recently mutations in exons 3
*Correspondence: Dr S Kopetz; E-mail: skopetz@mdanderson.org
Received 9 December 2015; revised 25 February 2016; accepted 8 March 2016; published online 7 June 2016
& 2016 Cancer Research UK. All rights reserved 0007 – 0920/16
FULL PAPER
Keywords: EREG; AREG; CIMP; cetuximab; methylation
British Journal of Cancer (2016) 114, 1352–1361 | doi: 10.1038/bjc.2016.87
1352 www.bjcancer.com |DOI:10.1038/bjc.2016.87
and 4 of KRAS and in NRAS have also been identified as predictive
of resistance to anti-EGFR therapies (Douillard et al, 2013).
However, resistance to anti-EGFR therapy exists even among
patients whose tumours are wild-type in KRAS and NRAS,
demonstrating the need to find and characterise additional
biomarkers of resistance.
The predictive impact of other mutations in signalling pathway
components downstream of EGFR has been unclear. Among stage
IV metastatic CRC patients treated with chemotherapy and
cetuximab, BRAF mutation is associated with poor prognosis (De
Roock et al, 2010; Tol et al, 2010), but is not necessarily predictive
of resistance to anti-EGFR therapy. A pooled analysis of two
studies that randomised KRAS wild-type metastatic CRC patients
to chemotherapy or chemotherapy plus cetuximab found that
BRAF mutant patients had inferior overall survival (OS) than
BRAF wild-type patients, but the addition of cetuximab was
associated with non-significant trend towards improved survival in
the BRAF mutant patients (HR 0.62, 95% CI 0.36–1.06, P¼ 0.076)
(Bokemeyer et al, 2012). There are also conflicting results
regarding the prognostic effect of PIK3CA mutations or PTEN
expression loss on patients treated with anti-EGFR therapy
(Laurent-Puig et al, 2009; Loupakis et al, 2009; De Roock et al,
2010; Tol et al, 2010; Karapetis et al, 2014). The role of these
mutations continues to undergo investigation.
A well-described biomarker associated with sensitivity to anti-
EGFR therapy is increased tumour gene expression of EREG and
AREG, which encode the EGFR ligands epiregulin and amphir-
egulin (Khambata-Ford et al, 2007; Jacobs et al, 2009). EREG and
AREG expression is inhibited by blockade of EGFR signalling and
is stimulated by treatment with other EGFR ligands, and it has
been hypothesised that higher expression of EREG and AREG may
indicate tumour cell dependence on an autocrine EGFR-activating
loop, and thus predict for increased susceptibility to anti-EGFR
therapy (Khambata-Ford et al, 2007). However, mechanisms
dictating varying levels of EREG or AREG expression remain
unclear.
The site of the primary tumour also appears to be predictive of
efficacy of anti-EGFR therapy. Clinical trials in patients with KRAS
exon 2 wild-type metastatic CRC reveal that patients with left-
sided colorectal primary tumours have superior progression-free
survival (PFS) on treatment with cetuximab-based regimens
compared with patients with right-sided primary tumours (Von
Einem et al, 2014; Brule et al, 2015). Although the mechanism of
this distinction is not defined, right-sided primary CRCs are
known to have distinct pathobiology and characteristics, including
higher rates of BRAF mutation, microsatellite instability (MSI-
high), and high CpG island methylator phenotype (CIMP-high)
(Yamauchi et al, 2012). CIMP-high tumours are marked by
widespread DNA hypermethylation, which can epigenetically
silence genes when occurring within promoter loci (Weisenberger
et al, 2006). We sought to determine whether there was an
association between global methylation status as assessed by CIMP
status, the methylation status of CpG islands within the AREG and
EREG promoters, the mRNA expression of AREG and EREG, and
the site of the primary colorectal tumour in multiple independent
data sets collected within the University of Texas MD Anderson
Cancer Center (MDACC) and through The Cancer Genome
Atlas (TCGA).
MATERIALS AND METHODS
Patient cohorts and data analysis. A cohort of 179 patients at
MDACC with stages I–IV CRC provided informed consent for
biomarker analyses on tumour tissue and retrospective analysis of
patient records for research purposes, and the study was approved
by the institutional review board. Eligible tumour specimens
required at least 30% tumour cells on central review by a certified
pathologist, and macrodissection of fresh frozen primary tumour
tissue was performed. Gene expression analysis was performed
using Agilent microarrays (Agilent Technologies, Santa Clara, CA,
USA). RNA was isolated and assessed for quality, and RNA of
adequate quality was amplified, labelled, and hybridised to the
microarray. Data are expressed as z-scores. Methylation profiling
was determined using the Illumina Infinium HumanMethyla-
tion450 BeadChip Kit (Illumina, San Diego, CA, USA), using
bisulphite sequencing of methylated sites to determine methylation
status at over 480 000 CpG sites covering 99% of Ref-seq genes.
Two additional cohorts of patients with stages II–IV colon or
rectal adenocarcinoma were analysed from data generated by
TCGA Research Network (http://cancergenome.nih.gov/): one
cohort, ‘TCGA27’ (n¼ 218), had gene expression analysed by the
Custom Agilent 244K gene expression microarray (Agilent
Technologies) and expressed as z-scores, and had methylation
profiling performed using the Illumina Infinium HumanMethyla-
tion27 BeadChip as described (The Cancer Genome Atlas
Network, 2012); and the second cohort, ‘TCGA450’ (n¼ 356),
had gene expression analysed by RNA sequencing (The Cancer
Genome Atlas Network, 2012) and expressed as log2-transformed
values, and also had methylation profiling performed using the
Illumina Infinium HumanMethylation450 BeadChip. In order to
evaluate the correlation of CpG island methylation and gene
expression, the TCGA pan-cancer data set was utilised (The
Cancer Genome Atlas Research Network et al, 2013).
A final independent cohort of 440 stage IV CRC MDACC
patients who had been heavily pretreated was enrolled on the
Assessment of Targeted Therapies Against Colorectal Cancer
(ATTACC) protocol between August 2010 and October 2013 for
screening and assignment to 10 individual phase I or II companion
clinical trials based on testing of banked formalin-fixed, paraffin-
embedded tumour tissue with gene sequencing, CIMP testing, and
immunohistochemical staining. The patients in the ATTACC
protocol provided informed consent for biomarker analyses on
archived tumour tissue and retrospective analysis of patient records
for research purposes, and the study was approved by the
institutional review board. Of the 440 patients enrolled in
ATTACC, 198 were KRAS exon 2 wild type by standard of care
testing and were successfully tested for CIMP status. From the
ATTACC specimens, bisulphite pyrosequencing of six well-
defined, traditionally utilised CpG islands (Toyota et al, 1999)
was performed, and specimens with X40% methylation of CpG
islands were deemed CIMP-high. The PCR primers used at MD
Anderson for bisulphite pyrosequencing CpG islands in p14, p16,
MLH1, MINT1, MINT2, and MINT31 are listed in Supplementary
Table 1A.
Definition of CIMP status. CIMP status was determined from
methylation arrays by using the following two methodologies:
the first method was based on assessment of the methylation status
of the six CpG islands used to determine CIMP status on clinical
specimens in the ATTACC cohort; and the second method
was based on clustering of methylation profiles using
methodology paralleling that in TCGA (The Cancer Genome
Atlas Network, 2012).
To extrapolate the CIMP status based on the six-locus clinical
panel from the Illumina Infinium HumanMethylation450 Bead-
Chip results, the PCR primers for the bisulphite-treated sequences
for p14, p16, MLH1, MINT1, MINT2, and MINT31 were obtained.
A search for the corresponding sequence within the human
genome was undertaken using BiSearch (http://bisearch.enzim.hu/)
(Tusnady et al, 2005; Aranyi et al, 2006), and the identity of the
sequence was verified by ensuring that the sequencing primer was
located within the identified region. To identify the corresponding
nucleotide location within GRCh37, NCBI Blast was performed
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(Supplementary Table 1B). Subsequently, the CpG islands from the
Illumina Infinium HumanMethylation450 array that were located
within the primer regions were determined, and 1–2 CpG islands
within the PCR-amplified regions were found for the MLH1,
MINT2, and MINT31 primers. For the MINT1, p14, and p16
primers, no CpG islands on the panel were found within the
amplified regions, although 1–2 CpG islands located o300
nucleotides away for each of the primer pairs were found
(Supplementary Table 1C). The beta-value of each of these CpG
islands was transformed to an M-value (Du et al, 2010), and the
distribution of M-values for each data set was plotted and found to
be bimodal. For each CpG island, a threshold was determined at
the point between the two modes to dichotomise the methylation
status in the MDACC data. This threshold was applied to the
M-value transformations of the TCGA data and was found to
also reflect the point between the two modes (Supplementary
Table 2A and B). Then, a voting scheme mirroring the clinical
CIMP panel was enacted to determine CIMP status (CIMP-high
represents 440% or X3/6 markers).
For the TCGA samples assayed with the Illumina Infinium
HumanMethylation27 BeadChip instead of the larger Illumina
Infinium HumanMethylation450 BeadChip, it was not possible to
align the clinical panel with existing CpG island probes. Instead, a
clustering method of methylation profiles was used, following the
methods described in the TCGA manuscript (The Cancer Genome
Atlas Network, 2012).
Cell line data sets. To determine the effect of hypomethylating
agents azacitidine and decitabine on methylation of specific CpG
island promoters, raw experimental data were obtained from
ArrayExpress database (www.ebi.ac.uk/arrayexpress) using acces-
sion number E-MTAB-417. In this study, HCT116 colon cancer
cells were treated with 1 mM azacitidine or decitabine for 24 h.
Subsequently, the Illumina Infinium HumanMethylation27
BeadChip was used to determine methylation status (Hagemann
et al, 2011).
To determine the effect of the hypomethylating agent
azacitidine on expression of EREG and AREG, experimental data
was obtained from the Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/) using accession number GSE57341.
In this study, a panel of 14 CRC cell lines was treated with 500 nM
of azacitidine for 72 h. Cells were harvested at 1, 3, 7, 10, 14, 21, or
28 days, and expression was assayed using the Agilent 44K
Expression Array (Li et al, 2014).
Statistical analysis. Gene expression microarray data were
provided as z-scores. RNA-seq data were provided as raw values
that were base 2 logarithmically transformed for statistical analysis.
To identify association between clinical characteristics and
expression or methylation levels, the Mann–Whitney U-test was
utilised if variables were dichotomous, or the Kruskal–Wallis test
was utilised if variables had 42 possible values. To perform
survival analysis with PFS, the Kaplan–Meier method was used and
significance testing was performed using the log-rank test.
Additional univariate and multivariate Cox regression analyses
were performed using IBM SPSS Statistics version 21 (Armonk,
NY, USA). In addition, integrated Bayesian analysis of high-
dimensional multiplatform genomics (iBAG) (Wang et al, 2013)
data was performed using the nonlinear approach (Jennings et al,
2013) to determine the percent of variability in expression that is
explained by methylation. This method involved fitting an additive
regression model in which expression was regressed on methyla-
tion and copy number as additive nonparametric predictors, with
residual error representing variability in expression not explained
by methylation or copy number, that is, explained by some other
upstream regulator. After model fitting, percent variability
explained by methylation, copy number, and other causes were
estimated through the corresponding coefficients of determination.
For the MDACC ATTACC cohort, to determine associations
with PFS and OS, multiple imputation methodology was used, with
predictor variables including age, sex, CIMP-high vs low/none,
right- vs left-sided primary tumours, duration of first EGFR
regimen, progression status, prior bevacizumab, presence or
absence of additional cytotoxic chemotherapy, PTEN status,
PIK3CA mutation status, BRAF mutation status, NRAS mutation
status, and number of prior chemotherapy regimens. Any missing
values were addressed using an assumption of missing at random
and multivariate normality using the MCMC method in SPSS
to create 20 imputed data sets. Subsequently, Cox proportional
hazards models were used to perform univariate and multi-
variate regression analyses for PFS with the first anti-EGFR
regimen or OS.
RESULTS
EREG and AREG expression are strongly inversely associated
with methylation of loci within the promoters of EREG and
AREG. A cohort of 179 MDACC patients with CRC had primary
tumour specimens assayed for EREG and AREG methylation and
expression. Characteristics of the patient cohort are described in
Supplementary Table 3. Eight out of nine CpG islands located
within the EREG gene promoter or body were significantly
inversely associated with expression, as were four out of five
CpG islands located within the AREG gene and promoter
(Supplementary Table 4A and B). The strongest correlation with
EREG expression was with the CpG island cg19308222
(r¼  0.726, Po10 6; Figure 1A). The strongest correlation
with AREG expression was with the CpG islands cg26611070
(r¼  0.520, Po10 6) and cg022334660 (r¼  0.501, Po10 6;
Supplementary Figure 1a and b). These findings demonstrate that
there is a significant inverse association between DNA methylation
and expression of EREG and AREG, and identify promoter
methylation as a significant regulatory mechanism of expression
of EREG and AREG.
To confirm these findings, the association of EREG and AREG
methylation and expression was determined in two independent
cohorts of colon and rectal adenocarcinoma cancer specimens
from the TCGA. In the TCGA450 cohort (n¼ 356; Supplementary
Tables 4A and B and 5), the strongest correlation with EREG
expression was again with the CpG island cg19308222
(r¼  0.671, Po10 6; Figure 1B), and the strongest correlation
with AREG expression was again with the CpG island cg02334660
(r¼  0.457, Po10 6; Supplementary Figure 1c and d). In the
TCGA27 cohort (n¼ 218; Supplementary Table 6), strong inverse
correlation was again observed between EREG expression and
cg19308222 (r¼  0.659, Po10 6; Figure 1C). Because the panel
of CpG islands tested for methylation was smaller in this array,
there were no CpG islands tested within the AREG promoter.
To put this strong negative correlation in context, among colon
adenocarcinoma specimens in the TCGA, the inverse correlation
between methylation at cg19308222 and EREG expression was the
219th out of 18 945 most-negative correlation (top 1.2%) and
between methylation at cg02334660 and AREG expression was the
1801th out of 18 945 (top 9.5%) among methylation/gene
expression pairs (Broad Institute TCGA Genome Data Analysis
Center, 2014b). Similarly, among rectal adenocarcinoma specimens
in the TCGA, the inverse correlation between methylation at
cg19308222 and EREG expression was the 155th out of 19 209
most-negative correlation (top 0.8%), and the inverse correlation
between methylation at cg26611070 and AREG expression was the
1686th out of 19 209 most-negative correlation (top 8.8%) among
methylation/gene expression pairs (Broad Institute TCGA Genome
Data Analysis Center, 2014a).
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iBAG analysis. Additional analysis was completed to determine
the extent to which variation in expression of EREG and AREG was
attributable to methylation, compared with copy number variation
or other unspecified upstream regulators, using iBAG (Wang et al,
2013). In the MDACC cohort, 64.5% of EREG expression variation
was explained by methylation of cg19308222, compared with 2.9%
by copy number variation and 32.7% from other causes. In AREG,
if considering cg02334660 alone, 33.8% of expression was
explainable by variation in methylation, compared with 0.5% by
copy number variation and 65.7% by other causes. If considering
cg2661070 alone, 34.8% of expression was explained by variation in
methylation, compared with 0.6% by copy number variation and
64.6% by other causes. In the TCGA27 cohort, 57.5% of EREG
expression variation was explained by methylation of the
cg19308222 locus, compared with 0.9% from copy number
variation and 41.7% from other causes. The variation for AREG
could not be determined as there was no AREG methylation locus
in the Illumina Infinium 27K panel.
By comparison, in a large set of 799 genes analysed by iBAG in
two CRC cohorts, both the TCGA27 cohort and the MDACC
cohort, we found the median percent of expression explained by
variation in methylation was 5.78%. Only 5 of these 799 genes
(0.63%) had 460% of expression variability explained by
methylation, placing EREG within the top 1% of genes whose
expression was predominantly modulated by methylation.
Demethylating agents decrease methylation levels and increase
expression of EREG. In order to evaluate whether methylation
modulates EREG expression, we utilised RNA arrays and Illumina
Infinium HumanMethylation27 BeadChip data sets for CRC cell
lines treated with azacitidine and decitabine. EREG methylation at
cg19308222 was significantly reduced by treatment with either
azacitidine or decitabine (Figure 1D). In contrast, the EREG
associated CpG site cg04941721 was not altered with either agent,
consistent with the limited correlation of this site with EREG
expression. No CpG probes for AREG are present on the Illumina
27K array, limiting evaluation of this target. Expression of EREG
was evaluated at various time points after 72 h of treatment with
azacitidine in a panel of 14 CRC cell lines, demonstrating a time-
dependent increase in expression of EREG, which was not seen in
AREG (Figure 1E and F).
Right-sided primary, CIMP-high, MSI-high, and BRAF-mutated
cancers are associated with higher levels of gene methylation and
lower levels of expression of EREG and AREG. Next, we
examined whether additional clinical and pathological character-
istics of CRC were associated with significant differences in
methylation and expression of AREG and EREG. In the MDACC
cohort, right-sided primary tumour, MSI-high status, BRAF V600E
mutant status, and mucinous histology were all associated with
significantly lower levels of AREG and EREG expression, and
significantly higher levels of methylation of the AREG loci
cg02334660 and cg26611070, and the EREG locus cg19308222
(Table 1 and Supplementary Figure 2). CIMP was defined by one
of two different methods, and CIMP-high status by either method
was associated with significantly lower AREG and EREG expres-
sion, and significantly higher methylation of EREG cg19308222
(Table 1 and Figure 2A and B). In the TCGA450 cohort, similar to
the MDACC results, MSI-high status, BRAF mutant status,
mucinous histology, and right-sided primary tumour were
significantly associated with lower levels of AREG and EREG
expression, and with higher levels of methylation at the AREG loci
cg02334660 and cg26611070, and the EREG locus cg19308222
(Table 2 and Supplementary Figure 4). CIMP-high status,
determined by clinical method, was again associated with lower
AREG and EREG expression, and with higher methylation of the
AREG and EREG loci (Figure 2C and D). In the TCGA27 cohort,
MSI-high status, BRAF mutant status, mucinous histology, and
right-sided primary tumour were all again associated with
significantly lower levels of AREG and EREG expression, and
significantly higher levels of methylation of the EREG locus
cg19308222 (Supplementary Table 7). In addition, CIMP-high
status, as assessed by clustering, was also significantly associated
with lower levels of AREG and EREG expression, and higher levels
of EREG methylation at cg19308222.
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Figure 1. EREG methylation is inversely associated with expression, and is modulated by hypomethylating agents. (A–C) Scatter plots of
methylation b-value at the EREG CpG island cg19308222 compared with EREG expression in the (A) MDACC cohort (n¼ 179), (B) TCGA450
cohort (n¼356), or (C) TCGA27 cohort (n¼ 218). (D) Methylation at cg19308222 after treatment with 1 mM azacitidine or decitabine for 24 h. (E and
F) Expression of EREG (A_23_P41344), but not AREG (A_23_P249071), is increased after treatment with 500 nM azacitidine for 72 h and cell
harvesting after the indicated duration. *Po0.05 compared with control.
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Among the subgroup of 84 patients in the MDACC cohort
known to be wild-type both in BRAF codon 600 and in KRAS
codons 12 and 13, right-sided primary tumour location remained
significantly associated with lower AREG and EREG expression,
and higher methylation of the AREG loci cg02334660 and
cg26611070, and the EREG locus cg19308222 (Supplementary
Table 8 and Supplementary Figure 3). In this subgroup, CIMP-
high status as determined by the clinical method was significantly
associated with higher methylation levels of EREG cg19308222 and
was non-significantly associated with lower EREG expression.
Similarly, in the subgroup of 163 patients in the TCGA450 cohort
who were wild-type both in BRAF and in KRAS codons 12 and 13,
MSI-high status, mucinous histology, and right-sided primary
tumour remained significantly associated with lower AREG and
EREG expression, and higher levels of methylation at the AREG
and EREG loci. CIMP-high status remained significantly associated
with lower EREG expression and higher levels of methylation at the
AREG and EREG loci.
Finally, among the subgroup of 134 patients in the TCGA450
cohort who were wild-type in BRAF, KRAS exons 2–4, and NRAS,
MSI-high status, mucinous histology, right-sided primary tumour,
and CIMP-high status remained significantly associated with lower
AREG and EREG expression, and higher levels of methylation at
the AREG and EREG loci (Supplementary Table 9 and
Supplementary Figure 5). Similarly, among the 100 patients in
the TCGA27 cohort who were wild-type in BRAF, KRAS, and
NRAS, a significant association with lower EREG and AREG
expression, and higher EREG cg19308222 methylation remained
with CIMP-high status, right-sided primary tumour, and MSI-high
status (Supplementary Table 7).
CIMP-high status is associated with inferior PFS to anti-EGFR
therapy in KRAS wild-type patients. An independent cohort of
198 patients with KRAS wild-type metastatic CRC enrolled in the
ATTACC protocol at MDACC was successfully tested for CIMP
status (Supplementary Table 10). Of this group, 173 patients had
previously been treated with an anti-EGFR therapy, and PFS with
the first anti-EGFR regimen was retrospectively determined in 167
patients. Of this group, 26.3% (44/167) patients were CIMP-high.
Compared with the CIMP-low/none group, the CIMP-high group
was significantly more likely to have right-sided primary tumour
(45.5% vs 23.6%, P¼ 0.011), MSI-high status (18.5% vs 1.6%,
P¼ 0.009), BRAF mutation (42.9% vs 6.9%, Po0.0001), and male
sex (77.3% vs 60.2%, P¼ 0.045).
Kaplan–Meier analysis found that among the entire cohort
of 167 KRAS wild-type patients, inferior PFS with the first
anti-EGFR therapy regimen was significantly associated with
CIMP-high status (median PFS 4.0 vs 6.5 mo, Po0.001),
BRAF mutation (median PFS 2.8 vs 6.5 mo, P¼ 0.004), NRAS
mutation (median PFS 4.4 vs 7.2 mo, P¼ 0.006), and right-
sided primary tumour (median PFS 4.7 vs 6.5 mo, P¼ 0.040)
(Figure 2E and F and Supplementary Figure 6a). These findings
were recapitulated on univariate analysis by Cox proportional
hazards regression analysis. On multivariate Cox regression
Table 1. Univariate analyses of clinical and pathological characteristics from the MDACC cohort (n¼179)
AREG expression
(z-score)
EREG expression
(z-score)
AREG methylation
cg02334660
AREG methylation
cg26611070
EREG methylation
cg19308222
Variables n Median P Median P Median P Median P Median P
CIMP status (clinical) 0.005 o0.001 0.243 0.182 o0.001
High 52 0.144 0.383 0.459 0.477 0.427
Low/none 127 0.142 0.187 0.435 0.449 0.207
CIMP status (cluster) 0.001 o0.001 0.034 0.033 o0.001
High 35 0.255 0.393 0.487 0.519 0.452
Low/none 143 0.134 0.153 0.429 0.446 0.225
Mucinous 0.005 o0.001 0.004 0.003 o0.001
Yes 29 0.185 0.698 0.517 0.547 0.423
No 130 0.137 0.144 0.425 0.44 0.23
Location of primary o0.001 o0.001 o0.001 o0.001 o0.001
Right-sided 82 0.12 0.258 0.489 0.518 0.331
Left-sided 77 0.193 0.252 0.395 0.413 0.2
MSI status o0.001 0.002 o0.001 o0.001 0.001
MSI-high 22 0.293 0.478 0.646 0.703 0.453
MSS 93 0.157 0.172 0.408 0.433 0.229
BRAF V600E o0.001 o0.001 o0.001 o0.001 o0.001
Mutant 19 0.275 0.775 0.542 0.556 0.452
Wild-type 133 0.154 0.172 0.42 0.442 0.229
KRAS codon 12/13 0.002 0.006 0.87 0.998 0.051
Mutant 49 0.061 0.196 0.448 0.457 0.298
Wild-type 103 0.163 0.189 0.423 0.453 0.232
PIK3CA 0.46 0.584 0.056 0.089 0.235
Mutant 21 0.088 0.138 0.482 0.509 0.282
Wild-type 131 0.064 0.079 0.423 0.444 0.241
Stage 0.952 0.6 0.281 0.293 0.905
2 74 0.052 0.108 0.466 0.47 0.244
3 78 0.095 0.012 0.426 0.443 0.268
4 7 0.016 0.317 0.399 0.428 0.229
Lymphovascular invasion 0.112 0.074 0.168 0.173 0.147
Yes 104 0.117 0.123 0.416 0.442 0.248
No 55 0.03 0.196 0.472 0.492 0.313
Abbreviations: CIMP¼CpG island methylator phenotype; MDACC¼MD Anderson Cancer Center; MSI¼microsatellite instability. P-values obtained by Mann–Whitney U-test if variable is
dichotomous or Kruskal–Wallis test if 42 variables.
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analysis by multiple imputations, NRAS mutation (HR 2.27, 95%
CI 1.25–4.13, P¼ 0.007), BRAF mutation (HR 2.50, 95% CI
1.22–5.13, P¼ 0.012), and CIMP-high status (HR 2.00, 95% CI
1.11–3.64, P¼ 0.022) remained significant. Right-sided primary
tumour was not significant (HR 1.43, 95% CI 0.86–2.36, P¼ 0.167)
(Table 3). In the subgroup with BRAF and NRAS wild-type disease,
inferior PFS with the first anti-EGFR regimen remained significantly
associated with CIMP-high status (median PFS 5.6 vs 9.0 mo,
P¼ 0.023) and trended with right-sided primary tumour (median
PFS 5.6 vs 9.0 mo, P¼ 0.053) on Kaplan–Meier analysis (Figure 2G
and Supplementary Figure 6b).
Notably, on univariate analysis of OS among the 198 patients,
with 162 events, CIMP-high status (HR 1.53, 95% CI 1.08–2.16),
right-sided primary tumour (HR 1.45, 95% CI 1.04–2.01), BRAF
mutation (HR 2.46, 95% CI 1.61–3.75), and NRAS mutation (HR
1.70, 95% CI 1.03–2.81) were significantly associated with inferior
survival. However, neither CIMP-high status nor right-sided
primary tumour were significantly associated with OS on multi-
variate analysis among the entire cohort or on univariate analysis
among the subgroup of 109 patients known to be wild-type in
BRAF and NRAS.
DISCUSSION
Our study is one of the first to identify CIMP status, and more
specifically methylation of loci within the EREG and AREG
promoters, as a determinant of EREG and AREG expression levels
and a prognostic biomarker with regards to PFS upon treatment
with anti-EGFR therapy in patients with metastatic CRC. Given the
association we and others have observed between EREG levels and
the site of primary tumour, this provides additional explanation for
the clinical differences observed in right- vs left-sided primary
tumours. Although our data are retrospective and are not derived
from clinical trials, the use of multiple independent data sets
available through the TCGA to validate our findings is a strength
of our study.
Although methylation of CpG islands within gene promoters is
generally known to be associated with downregulation of
expression, it remains unclear which methylated loci are most
important in driving differential expression. Although the TCGA
Pan-Cancer project has identified for each gene the single CpG
island most inversely correlated with expression, our results
extended these results specifically to CRCs. For EREG, we found
that the CpG island cg19308222, which was most strongly inversely
correlated with expression in the Pan-Cancer project, was again the
most inversely correlated CpG island in CRC. However, for AREG,
we found that the CpG islands cg02334660 and cg26611070 had
the strongest inverse correlation with expression in CRC, while in
the Pan-Cancer project, cg03244277 had the strongest inverse
correlation. Indeed, both cg02334660 and cg26611070 are located
within the body of the AREG gene. Although gene-body
methylation is thought to be associated with increased expression
(Yang et al, 2014), body methylation may conversely function to
repress activation of intragenic promoters and functions in a
tissue-specific context (Maunakea et al, 2010; Jones, 2012). The
tissue-specific effects of methylation at specific loci in specific
genes requires further investigation, as this may explain the
differences in which locus was selected as the most anti-correlated
with expression.
The significant contribution of EREG and AREG methylation on
gene expression has not been previously well described. A small
in vitro study of gastric cancer cell lines revealed inverse correlation
between EREG promoter methylation and expression (Yun et al,
2012). Indeed, iBAG analysis demonstrated that B57–65% of
P < 0.001 P < 0.001 P < 0.001 P < 0.001
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Figure 2. CIMP status is associated with EREG methylation and expression, and with the duration of progression-free survival with anti-EGFR
therapy. (A and B) BLiP plots comparing (A) z-score of EREG expression and (B) methylation levels at cg19308222 in CIMP-high vs low/none as
determined by clinical method in the MDACC cohort (n¼ 179). (C and D) BLiP plots comparing (C) log2-transformed EREG expression and (D)
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variation of expression in EREG was attributable to methylation of
cg19308222, and 33–35% of variation of expression in AREG was
attributable to methylation of the AREG loci cg02334660 or
cg2661070. Furthermore, treatment of CRC cell lines with
demethylating agents indeed resulted in decreased methylation at
the cg19308222 locus and increased expression of EREG. This
provides the strongest evidence to date that methylation of these
important EGFR ligands is a significant likely mechanism of
regulation of expression, and also suggests that this mechanism can
be manipulated by treatment with hypomethylating agents.
Several studies have already established that high expression of
EREG and AREG is associated with improved outcomes with anti-
EGFR therapy in refractory metastatic CRC. A study of tumours
from 110 metastatic CRC patients treated with cetuximab found
that high EREG or AREG expression was associated with longer
PFS (HR 0.47, P¼ 0.0002; and HR 0.44, Po0.0001, respectively)
(Khambata-Ford et al, 2007), although it was unclear whether there
was an interaction of EREG and AREG expression level with KRAS
or BRAF mutation status. Another study in 121 irinotecan-
refractory KRAS wild-type metastatic CRC patients who received
anti-EGFR therapy on clinical trials found that EREG and AREG
expression was significantly associated with response rate, disease
control, PFS, and OS with anti-EGFR therapy, with the predictive
value of EREG expression superior to that of AREG expression
(Jacobs et al, 2009). Analysis from the CO.17 trial of cetuximab in
patients with refractory metastatic CRC found cetuximab had a
larger effect in improvement of OS and PFS in KRAS wild-type and
EREG expression-high patients (Jonker et al, 2014). Similarly,
results from the PICCOLO trial of second-line panitumumab and
irinotecan in metastatic CRC found significant improvement in
PFS in patients with either EREG or AREG expression in the
highest tertile (Seligmann et al, 2016). Finally, a retrospective
evaluation of expression of 110 candidate genes from 144 primary
tumours of KRAS wild-type refractory metastatic CRC patients
found that high EREG and AREG expression was strongly
associated with improved PFS and disease control rate with
cetuximab (Baker et al, 2011). In contrast, two first-line studies
failed to demonstrate that EREG or AREG expression is predictive
of benefit with cetuximab when combined with multi-agent
chemotherapy backbones (Adams et al, 2012; Cushman et al,
2015). Moreover, these studies did not further describe additional
clinical and pathological variables that we now know may have
impacted EREG and AREG expression.
Additional data reveal that patients whose tumours have high
EREG and AREG expression are more likely to have clinical and
tumour biological characteristics similar to those we found. Indeed,
Table 2. Univariate analyses of clinical and pathological characteristics from the TCGA450 cohort (n¼356)
AREG expression
(log2)
EREG expression
(log2)
AREG methylation
cg02334660
AREG methylation
cg26611070
EREG methylation
cg19308222
Variable n Median P Median P Median P Median P Median P
CIMP status o0.001 o0.001 o0.001 o0.001 o0.001
High 97 9.474 7.657 0.541 0.572 0.605
Low/none 259 10.137 10.096 0.432 0.452 0.211
Location of primary o0.001 o0.001 o0.001 o0.001 o0.001
Right-sided 169 9.597 8.408 0.508 0.5339 0.4466
Left-sided 179 10.299 10.346 0.4346 0.4481 0.1859
MSI status o0.001 o0.001 o0.001 o0.001 o0.001
MSI-high 52 8.281 5.135 0.7399 0.7882 0.6063
MSS 302 10.139 10.059 0.4377 0.4579 0.2279
BRAF V600E o0.001 o0.001 o0.001 o0.001 o0.001
Mutant 26 8.175 4.696 0.6727 0.6946 0.6581
Wild-type 262 10.147 10.104 0.4536 0.4689 0.2331
KRAS codon 12/13 0.331 0.313 0.862 0.854 0.133
Mutant 99 9.714 9.174 0.475 0.492 0.338
Wild-type 189 10.136 10.034 0.467 0.479 0.239
KRAS exons 2–4 0.249 0.206 0.374 0.401 0.335
Mutant 114 9.728 9.005 0.441 0.47 0.324
Wild-type 174 10.16 10.146 0.473 0.49 0.239
NRAS 0.725 0.763 0.153 0.2 0.618
Mutant 15 10.066 10.349 0.4371 0.4556 0.2851
Wild-type 273 10.063 9.661 0.4747 0.4923 0.2503
PIK3CA 0.566 0.94 0.834 0.714 0.458
Mutant 65 9.805 9.621 0.4812 0.4923 0.3232
Wild-type 223 10.074 9.757 0.4621 0.4844 0.2464
Stage 0.575 0.423 0.532 0.497 0.372
1 53 9.874 8.685 0.475 0.506 0.504
2 125 9.742 9.464 0.458 0.468 0.28
3 112 9.921 9.449 0.481 0.476 0.284
4 49 10.299 10.26 0.471 0.479 0.209
Lymphovascular invasion 0.443 0.871 0.936 0.961 0.536
Yes 91 9.846 9.661 0.498 0.52 0.285
No 217 9.903 9.464 0.48 0.497 0.282
Mucinous o0.001 o0.001 o0.001 o0.001 o0.001
Yes 39 8.77 6.125 0.544 0.579 0.561
No 311 10.102 9.919 0.452 0.468 0.239
Abbreviations: CIMP¼CpG island methylator phenotype; MSI¼microsatellite instability; TCGA¼The Cancer Genome Atlas. P-values obtained by Mann–Whitney U-test if variable is
dichotomous or Kruskal–Wallis test if 42 variables.
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data from 952/1630 samples from the randomised phase III COIN
(addition of cetuximab to oxaliplatin-based first-line combination
chemotherapy for treatment of advanced CRC) trial showed that
high expression of EREG and AREG was significantly associated
with wild-type KRAS, wild-type BRAF, left-sided primary colon
tumour, and microsatellite stable disease (Adams et al, 2012). An
independent study also found that left-sided primary colon
carcinomas were more likely to have epiregulin overexpression
(Missiaglia et al, 2014). Moreover, data from 331/696 samples from
the randomised PICCOLO (Panitumumab, irinotecan, and ciclos-
porin in CRC) trial in second-line treatment of metastatic CRC
similarly found that high expression of EREG and AREG was
associated with wild-type BRAF and left-sided primary colon
tumour (Seligmann et al, 2016).
Also, multiple trials showed that patients with KRAS wild-type
left-sided CRC have improved outcomes upon treatment with
cetuximab than those with right-sided CRC. In the AIO KRK-0104
trial, 146 patients were randomised to receive first-line CAPOX
with cetuximab or CAPIRI (capecitabine/irinotecan) with cetux-
imab. In this trial, 95/146 patients had KRAS codon 12 and 13
wild-type tumour, with 68 left-sided and 27 right-sided primary
tumours. Patients with left-sided KRAS exon 2 wild-type cancers
had superior OS (HR 0.63, P¼ 0.016) and PFS (HR 0.67, P¼ 0.02)
than patients with right-sided tumours. In patients with KRAS/
BRAF wild-type tumours (n¼ 79), median PFS was 8.2 vs 5.9 mo
(HR 0.81, P¼ 0.47) and median OS was 27.3 vs 16.2 mo (HR 0.60,
P¼ 0.11; Von Einem et al, 2014). In the CO.17 study, 399 patients
with metastatic CRC were randomised to receive cetuximab or best
supportive care. In the cohort of patients with KRAS exon 2 wild-
type status, there was a significant interaction between site of
primary tumour and PFS benefit with cetuximab (for left-sided
tumours, HR 0.28 and Po0.0001; for right-sided tumours, HR 0.73
and P¼ 0.26), with predictive effect interaction term (P¼ 0.002)
(Brule et al, 2013; Brule et al, 2015).
Notably, although CIMP-high status and right-sided primary
CRC were both associated with significantly inferior OS on
univariate analysis, neither remained significant after adjusting for
NRAS and BRAF status. As CIMP-high status remained signifi-
cantly associated with PFS with anti-EGFR therapy after adjusting
for these variables, this suggests that the inferior anti-EGFR PFS of
CIMP-high patients is not solely due to an overall inferior
prognosis, at least among the KRAS/NRAS/BRAF wild-type
subpopulation. Indeed, several studies have noted inferior overall
prognosis among patients with low EREG/AREG expression
(Pentheroudakis et al, 2013; Stahler et al, 2016) or right-sided
primary CRC (Loupakis et al, 2015). These studies are variable in
whether they included only patients with KRAS wild-type tumours,
whether they limited analysis to patients with anti-EGFR therapy
only, and whether EREG and AREG were treated as a continuous
or categorical variable and how any cut points were defined.
Furthermore, none included CIMP status in their multivariable
analyses. Furthermore, recent data from the PICCOLO study show
that although high EREG and AREG levels were associated with
improved OS among all patients and among the RAS wild-type
subgroup, neither was significantly associated with OS among the
RAS and BRAF wild-type subgroup. In that study, site of primary
tumour was not associated with PFS or OS (Seligmann et al, 2016).
Additional studies to confirm these findings in prospectively
collected data will be important in determining the predictive vs
prognostic role of these variables.
Previously, there had not been data for a plausible biological
explanation for the differential outcomes of left- and right-sided
primary CRCs with cetuximab-based treatment, but our findings
provide evidence that variation in EREG and AREG methylation,
and expression contribute to these differences (Figure 3). Although
there is ample existing evidence of the association of right-sided
primary cancers with CIMP-high status, our analysis provides a
novel association between right-sided and CIMP-high CRCs with
increased methylation specifically of the critical CpG islands within
EREG and AREG that have the strongest inverse association with
EREG and AREG expression. Accordingly, there is also an
association with low EREG and AREG expression. Several studies
have corroborated that low EREG and AREG expression are
associated with inferior outcomes with cetuximab therapy, even if
there is conflicting evidence whether EREG and AREG are
Table 3. Univariate Cox regression analysis and multivariate
Cox regression analysis after multiple imputations of MDACC
ATTACC cohort for PFS
Variable Hazard ratio (95% CI) P
Univariate analysis
CIMP-high 2.38 (1.47–3.85) 0.00043
Right-sided 1.56 (1.01–2.41) 0.043
BRAF mutant 2.14 (1.26–3.65) 0.005
NRAS mutant 2.12 (1.23–3.65) 0.007
PIK3CA mutant 0.97 (0.53–1.77) 0.92
PTEN loss 1.07 (0.57–2.03) 0.828
MSI-high 1.27 (0.39–4.12) 0.691
Non-white 1.24 (0.78–1.96) 0.362
Age 0.98 (0.96–1.00) 0.055
Male sex 1.07 (0.72–1.60) 0.727
Prior bevacizumab before EGFR 1.26 (0.76–2.07) 0.368
EGFR monotherapy 1.49 (0.75–2.97) 0.26
No. of prior chemo regimens 1.18 (0.91–1.53) 0.203
Multivariate analysisa
CIMP-high 2.00 (1.11–3.64) 0.022
Right-sided 1.43 (0.86–2.36) 0.167
BRAF mutant 2.50 (1.22–5.13) 0.012
NRAS mutant 2.27 (1.25–4.13) 0.007
Abbreviations: ATTACC¼Assessment of Targeted Therapies Against Colorectal Cancer;
CI-confidence interval; CIMP¼CpG island methylator phenotype; MDACC¼MD Anderson
Cancer Center; PFS¼progression-free survival.
aAdjusted for the number of prior regimens, age, prior bevacizumab, and use of anti-EGFR
as monotherapy or in combination with chemotherapy.
↑ CpG island methylation
↑ EREG/AREG methylation
↓EREG/AREG expression
Inferior outcomes
with cetuximab
↓ CpG island methylation
↓ EREG/AREG methylation
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Superior outcomes
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Figure 3. Left- and right-sided primary CRCs have distinct
pathobiology, with different rates of CIMP, and contrasting levels of
methylation and gene expression of EREG and AREG, providing a
unifying explanation for differences in outcomes with anti-EGFR
therapy like cetuximab.
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predictive or merely prognostic. Nevertheless, these data are
consistent with our retrospective analysis showing that CIMP-high
status is associated with inferior PFS with anti-EGFR-including
therapy.
Although our findings unify disparate observations and
associations between location of primary tumour, expression of
EREG and AREG, and differential responses to cetuximab, they are
based on retrospective analysis of several different data sets and
thus cannot ascertain causality. Prospective incorporation of these
variables into the analysis of adequately powered future rando-
mised controlled trials of anti-EGFR therapies in first-line and
refractory metastatic CRC will be necessary to determine whether
CIMP status and methylation level of EREG and AREG are truly
predictive of response. Further investigation is warranted into
whether differential methylation and expression of additional
genes in CIMP-high patients contribute to resistance to anti-EGFR
therapy.
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